No abstract available.
Sparganosis*

The double pylorus-is a fistulous communication between the gastric antrum and duodenal bulb, usually extending from the lesser curvature of the stomach to the superior aspect of the duodenal bulb, and seperated by septum or bridge of normal mucosa. Although its incidence is rare, reports concerning double pylorus are increasing with the recent development of upper gastrointestinal endoscopy and more awareness of this abnormality. We recently experienced two cases of double pylorus; an aquired one in 72-year old male who had an another opening with healing ulcer at the superior aspect of the original pyloric channel, central erosion with clubbing and fusion of mucosal folds at the greater curvature of the lower body and a 3 x 4 cm sized ulcer at the lesser curvature of the lower body, and the other congenital one in 53-year old male who had an another opening at the superior aspect of the original pyloric channel with histologically intact muscularis mucosa in the pyloric septum with no evidence of chronic peptic ulcer scarring. We report here two cases of double pylorus, one-acquired, and the other-congenital, with a review of the literature.
Aged ; Cicatrix ; Endoscopy, Gastrointestinal ; Humans ; Incidence ; Male ; Middle Aged ; Mucous Membrane ; Peptic Ulcer ; Pyloric Antrum ; Pylorus ; Stomach ; Stomach Ulcer ; Ulcer

No abstract available.
Colonoscopy*

No abstract available.

Hepatocellular carcinoma (HCC) is a major global health problem, which has a grave morbidity and mortality. Over the past few decades, no effective systemic therapeutic modalities have been established for patients with the unresectable HCC in advanced stage. Sorafenib is a small molecule that blocks cancer cell proliferation by targeting the intracellular signaling pathway at the level of Raf-1 and B-Raf serine-threonine kinases, and exerts an anti-angiogenic effect by targeting the vascular endothelial growth factor receptor-1, 2 and 3, and platelet-derived growth factor receptor-beta tyrosine kinases. Recently, two clinical successful applications, SHARP and Asia-Pacific trial, of multikinase inhibitor sorafenib represent a significant advance in the treatment of advanced HCC patients without a curative chance. However, because the results of clinical trials show diverse responses in a subset of HCC patients, a molecular classification of HCC through the excavation of specific biomarkers related to its biological behavior is necessary for sorting HCC patients to each group with a biological homogeneity, ultimately leading to the most suitable individualization of molecular targeted therapy in HCC.
Antineoplastic Agents/therapeutic use ; Benzenesulfonates/therapeutic use ; Carcinoma, Hepatocellular/pathology/secondary/*therapy ; Humans ; Liver Neoplasms/blood supply/pathology/*therapy ; Neovascularization, Pathologic ; Proto-Oncogene Proteins B-raf/antagonists & inhibitors/metabolism ; Proto-Oncogene Proteins c-raf/antagonists & inhibitors/metabolism ; Pyridines/therapeutic use ; Receptors, Platelet-Derived Growth Factor/antagonists & inhibitors/metabolism ; Receptors, Vascular Endothelial Growth Factor/antagonists & inhibitors/metabolism ; Signal Transduction

No abstract available.
Hepatopulmonary Syndrome* ; Lung* ; Perfusion*

Transient hyperkalemia is well known to occur in man following intravenous administration of succinylcholine chloride. We studied the change of the serum potassium concentration after injection of succinylcholine in nonburn patients and electricburn patients, physical status 1 or 2 adopted by the American Society of Anesthesiologists. We compared two groups: Non-burn patient group(Group 1) as control, Electric burn patient group (Group 2) as experimental. The following results were obtained: 1) In non-burn patient group(Group 1) serum potassium concentration was slightly decreased in the 1st, 2nd, 3rd, 4th, 5th, 6th and 10th minute after succinylcholine injection compared with control, but nostatistical significance was noticed in this group. 2) In electric burn patient group (Group 2) serum potassium concentration was maximally increased compared with the controls. Statistical significance was noticed at the 2nd and 3rd minute after succinylcholine injection in this group.
Administration, Intravenous ; Burns, Electric* ; Humans ; Hyperkalemia ; Potassium ; Succinylcholine*

Cancer metastasis, a complex and sequential network of cellular events involved in the migration and establishment of malignant cells from original site to distant foci, is an important and significant contributor to morbidity and mortality of cancer patients. Despite the clinical importance of cancer metastasis, its molecular and biochemical mechanism remains unclear. The identification of tumor suppressor gene confirmed that metastasis might involve the functional loss of genes that maintain the cellular differentiation optimally. Metastasis suppressor is defined by the ability to reduce the metastatic property of cancer cells without affecting its tumorigenesis. Since NM23 was first identified in 1988 as a metastasis suppressor, several metastasis suppressor genes have been identified and characterized. In this article, we review the complex and multi-step process of cancer metastasis and describe the recent progress of metastasis suppressors in the studies of identified. Consequently, we hope to introduce the new therapeutic target for the metastasis suppressors in cancer patients.
English Abstract ; *Genes, Tumor Suppressor ; Humans ; Neoplasm Metastasis/genetics/*physiopathology ; Nucleoside-Diphosphate Kinase/genetics/metabolism

In order to find a highly efficient compound against Clonorchis infection, the anthelmintic activity of disophenol, Tremerad (SYD-230), dithiazanine iodide, dehydroemetine-late-release tablets(RO 1-9334/20), niridazole (Ambilhar), hexachlorophene (G-11), Hetol(1, 4-bis-trichloromethylbenzol) and Bilevon (niclofolan) was tested against Clonorchis sinensis experimentally infected rabbits. All drugs showed a progressive increase in efficacy as the dose rate. They were highly efficient against Clonorchis infection if sufficiently high, potentially toxic doses were given. The efficacy was evaluated by the number of detected worms with vital condition at autopsy after the treatment with above drugs. The high efficacy was observed at the following dose rates of each drugs, i.e. disophenol at a single dose of 30 mg/kg, Tremerad at the daily dose of 200 mg/kg for 10 consecutive days, dithiazanine iodide at the daily dose of 50 mg/kg for 6 consecutive days, dehydroemetine at the daily dose of 10 mg/kg for 10 consecutive days, hexachlorophene at the daily dose of 20 mg/kg for 10 to 15 consecutive days, Hetol at the daily doses from 50 to 100 mg/kg for 5 to 10 consecutive days, and Bilevon at a single dose of 8 mg/kg. Moderate effectiveness was shown in niridazole at the dose of 25 mg/kg for 10 days medication. The use of these anthelmintics for the clinical treatment of Clonorchis sinensis infection is discussed.
parasitology-helminth-trematoda ; chemotherapy-Clonorchis sinensis ; clonorchiasis-rabbit ; disophenol ; Tremerad (SYD-230) ; dithiazanine iodide ; dehydroemetine-late-release tablets(RO 1-9334/20) ; niridazole (Ambilhar) ; hexachlorophene (G-11) ; Hetol(1, 4-bis-trichloromethylbenxol) ; Bilevon (niclofolan)

The treatment of chronic viral hepatitis is aimed to prevent the progression to cirrhosis and hepatocellular carcinoma, eventually increasing the survival of the patients through biochemical, virological, and histological improvement. Recently, international and domestic consensus on management guidelines for chronic viral hepatitis B and C have been announced and recommended. Interferon-alpha, lamivudine, or adefovir dipivoxil, approved by FDA, can be used in the treatment of chronic hepatitis B according to the patient and virus characteristics, while the internationally standardized antiviral regimen for chronic hepatitis C is a combination therapy of pegylated interferon-alpha and ribavirin. Among these antiviral agents, adefovir dipivoxil, a nucleoside analogue of adenosine monophosphate, is known to be effective in treatment of chronic hepatitis B with the lamivudine-resistant YMDD mutant. The antiviral treatment of chronic viral hepatitis can be individualized to get the maximal treatment effect in a cost-effective manner through taking consideration of the patient status, side effects of antiviral agents, administration route, insurance criteria, and the patient' motivation toward medical treatment.
Adenosine Monophosphate ; Antiviral Agents ; Carcinoma, Hepatocellular ; Consensus ; Fibrosis ; Hepatitis ; Hepatitis B ; Hepatitis B, Chronic* ; Hepatitis C, Chronic ; Hepatitis, Chronic* ; Humans ; Insurance ; Interferon-alpha ; Lamivudine ; Motivation ; Ribavirin